| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.33 | 0.07 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.08 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.08 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.3 | 0.08 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.052 | 0.08 |